Nov 15, 2019 8:30 am EST Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update
Nov 11, 2019 7:00 am EST Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting
Nov 05, 2019 8:00 am EST Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment
Oct 24, 2019 9:00 am EDT Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting
Aug 14, 2019 7:00 am EDT Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update
Aug 12, 2019 7:00 am EDT Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110
Aug 07, 2019 11:15 am EDT Heat Biologics CEO and Lead Director to Participate in German Investor Forums
Jul 09, 2019 8:00 am EDT Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial
Jun 03, 2019 6:55 am EDT Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure
May 20, 2019 8:30 am EDT Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference